U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H14BrN3O3
Molecular Weight 376.205
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of WHI-P 154

SMILES

COC1=C(OC)C=C2C(NC3=CC(Br)=C(O)C=C3)=NC=NC2=C1

InChI

InChIKey=CBIAKDAYHRWZCU-UHFFFAOYSA-N
InChI=1S/C16H14BrN3O3/c1-22-14-6-10-12(7-15(14)23-2)18-8-19-16(10)20-9-3-4-13(21)11(17)5-9/h3-8,21H,1-2H3,(H,18,19,20)

HIDE SMILES / InChI

Molecular Formula C16H14BrN3O3
Molecular Weight 376.205
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/9796979 | https://www.ncbi.nlm.nih.gov/pubmed/27119652

WHI-P154 is an inhibitor of Janus-activated kinase JAK3. Also this drug inhibits other common kinases including EGFR, Src, Abl, VEGFR and others. WHI-P154 is potent inhibitor of glioblastoma cell adhesion and migration. Further preclinical development of WHI-P154 may provide the basis for the design of more effective adjuvant chemotherapy programs for glioblastoma multiforme. Treatment of ALK inhibitor, WHI-P154 resulted in the down-regulation of aberrant anaplastic lymphoma kinase (ALK) signaling, shrinkage of tumor, and suppression of metastasis and significantly improved survival of ALK mutant-bearing mice.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells.
1998 Jun
The specificity of JAK3 kinase inhibitors.
2008 Feb 15
Differential regulation of proliferation and differentiation in neural precursor cells by the Jak pathway.
2010 Oct
Patents

Sample Use Guides

Mouse: 1 mg/kg per day
Route of Administration: Intravenous
In Vitro Use Guide
WHI-P154 exhibited significant cytotoxicity against the U373 human glioblastoma cell line in three of three independent experiments with a mean (± SE) IC50 of 167.4 uM and a composite survival curve IC50 of 158.5 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:57:11 GMT 2023
Edited
by admin
on Sat Dec 16 11:57:11 GMT 2023
Record UNII
PG8BT6T9MB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
WHI-P 154
Common Name English
2-BROMO-4-((6,7-DIMETHOXY-4-QUINAZOLINYL)AMINO)PHENOL
Systematic Name English
JAK3 INHIBITOR II
Common Name English
PHENOL, 2-BROMO-4-((6,7-DIMETHOXY-4-QUINAZOLINYL)AMINO)-
Systematic Name English
4-(3'-BROMO-4'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE
Systematic Name English
Code System Code Type Description
FDA UNII
PG8BT6T9MB
Created by admin on Sat Dec 16 11:57:11 GMT 2023 , Edited by admin on Sat Dec 16 11:57:11 GMT 2023
PRIMARY
PUBCHEM
3795
Created by admin on Sat Dec 16 11:57:11 GMT 2023 , Edited by admin on Sat Dec 16 11:57:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID60274407
Created by admin on Sat Dec 16 11:57:11 GMT 2023 , Edited by admin on Sat Dec 16 11:57:11 GMT 2023
PRIMARY
CAS
211555-04-3
Created by admin on Sat Dec 16 11:57:11 GMT 2023 , Edited by admin on Sat Dec 16 11:57:11 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
IC50